Keywords: hematopoietic progenitors; microenvironmental progenitors; acute myelogenous leukemia; chemotherapy; LTC-IC; hematopoietic engraftment Since reduced marrow cellularity and prolonged pancytopenia following autologous bone marrow transplantation (ABMT) have been frequently observed in patients with acute myelogenous leukemia (AML)
7,8
not significantly reduced as compared to normal conDespite such chemotherapy-induced defective progenitor trols (48 ± 6 vs 52 ± 7, P р 0.73). Seventeen AML strocell growth, the reinfusion of autologous marrow can reconmal layers were tested for their capacity to support the stitute the hematopoietic system, even in acute myelogengrowth of allogeneic hematopoietic progenitors. Seven ous leukemia (AML) patients treated with remission inducsamples failed to support any progenitor cell growth, tion regimens exerting a significant marrow toxicity.
9,10
seven had a significantly lower supportive activity as Recently, therapeutic trials have been conducted in AML compared to normal stromal layers (13 ± 5 vs 249 ± 56, patients which were aimed at evaluating the efficacy of P р 0.002), whereas three cultures could not be anainduction and consolidation regimens containing new antilyzed due to contamination. In conclusion, induction leukemic drugs, such as idarubicin or mitoxantrone. 11 AML and consolidation regimens used in AML patients of the patients included in the AML10 GIMEMA/EORTC pilot AML10 protocol induce a markedly defective in vitro study receiving idarubicin, cytosine arabinoside, and etopogrowth of primitive hematopoietic progenitors and a side (ICE) as induction therapy and mitoxantrone and cytosevere functional defect of marrow stroma. The associsine arabinoside (NOVIA) as consolidation therapy, have ation of hematopoietic with microenvironmental dambeen reported to have reduced marrow cellularity, often age might play a key role in the delayed hematopoietic preventing marrow harvest and dramatically reducing the regeneration observed following ABMT in patients of feasibility of autologous bone marrow transplantation the AML10 trial.
(ABMT). 12, 13 In addition, as compared to historical controls treated with the conventional daunorubicin and cytosine arabinoside (D3A7) protocol, 14 patients autografted with
Correspondence: Dr C Carlo-Stella, Cattedra di Ematologia, Università di marrow harvested following the ICE/NOVIA regimens, Parma, Via Gramsci, 14, I-43100 Parma, Italy Received 21 February 1997; accepted 26 May 1997 have experienced a significantly prolonged pancytopenia associated with increased transplant-related mortality. apy or at marrow harvest, respectively. Normal values for bone marrow progenitor cell growth were provided from Reduced marrow cellularity and poor graft function were also observed in patients included in the AML10 57 healthy subjects (38 males, 19 females) with a median age of 42 years (range, 20-67). randomized trial who received the same intercalating drug (idarubicin, mitoxantrone or daunorubicin) during remission induction and consolidation therapy. 13 These Cell separation procedures clinical findings prompted us to hypothesize that administration of chemotherapy regimens of the AML10 protocols After informed consent was given, bone marrow was obtained by aspiration from the posterior iliac crest and could result in severe toxic effects involving both hematopoietic and microenvironmental progenitor cell compartmononuclear cells (MNC) were separated by centrifugation (400 g, 30 min, 4°C) on a Ficoll-Hypaque gradient (density ments.
It was, therefore, the aim of the present study to investi-= 1.077 g/ml). Interface cells were washed and suspended in RPMI-1640 (Gibco, Grand Island, NY, USA) supgate marrow hematopoietic and microenvironmental progenitors in AML patients of the AML10 pilot or ranplemented with 20% fetal bovine serum (FBS; Hyclone, Logan, UT, USA). domized trials. Hematopoietic progenitors were studied by means of a short-term methylcellulose assay allowing us to quantitate multipotent (CFU-Mix), erythroid (BFU-E) and CFU-Mix, BFU-E and CFU-GM assay granulocyte-macrophage (CFU-GM) progenitors as well as a long-term assay which allows us to quantitate primitive
The assay for multilineage colony-forming units (CFUMix), erythroid bursts (BFU-E), and granulocyteprogenitors capable of initiating and sustaining hematopoiesis in long-term culture (long-term culture initiating cells, macrophage colony-forming units (CFU-GM) was carried out as described elsewhere. 18 Briefly, 5 × 10 4 MNC were LTC-IC). 15 The marrow microenvironment was studied by quantitating marrow fibroblast colony-forming cells (CFUplated in 35-mm Petri dishes in 1-ml aliquots of Iscove's modified Dulbecco's medium (IMDM; Seromed, Berlin, F) and by evaluating the capacity of stromal layers to support the growth of allogeneic normal hematopoietic Germany) containing: 30% FBS (Stem Cell Technologies, Vancouver, Canada); 10 −4 m 2-mercaptoethanol (Gibco), progenitors. 16 and 1.1% (w/v) methylcellulose. Cultures were stimulated with interleukin-3 (10 ng/ml; Sandoz, Basel, Switzerland), granulocyte colony-stimulating factor (10 ng/ml, Amgen,
Materials and methods
Thousand Oaks, CA, USA), granulocyte-macrophage colony-stimulating factor (10 ng/ml; Sandoz) and erythroPatients poietin (3 U/ml; Amgen). Progenitor cell growth was evaluated after incubation (37°C, 5% CO 2 ) for 14-18 days in a Twenty-six patients (12 males, 14 females) with a median age of 45 years (range, 14 to 59) and a diagnosis of AML humidified atmosphere. Four dishes were set up for each individual data point per experiment. CFU-Mix defined as were included in this study. The diagnosis of AML was based on the criteria of the French-American-British containing at least erythroid and granulocytic cells, BFU-E with у500 cells and CFU-GM with у40 cells were (FAB) Cooperative Group. 17 The study population included patients with different FAB subtypes (M1 (n = 3), M2 (n scored from the same dish. = 9), M4 (n = 8), M5 (n = 5), and M6 (n = 1) ). All patients had been treated at the Department of Hematology, 'La Long-term culture-initiating cell (LTC-IC) assay Sapienza' University, Rome, according to different remission induction and consolidation protocols. Nine
The long-term culture-initiating cell (LTC-IC) assay was performed according to a previously described techpatients enrolled in the AML10 GIMEMA/EORTC pilot study received the ICE (idarubicin, cytosine arabinoside, nique. 15, 19 Briefly, MNC were resuspended in complete medium consisting of alpha-medium (Gibco) supplemented etoposide) regimen as remission induction therapy and the NOVIA (mitoxantrone, cytosine arabinoside) regimen as with fetal bovine serum (12.5%), horse serum (12.5%), lglutamine (4 mm), 2-mercaptoethanol (10 −4 m), inositol (0.2 consolidation therapy, whereas the remaining 17 patients were randomized to receive three different regimens mm), folic acid (20 m) and freshly dissolved hydrocortisone (10 −6 m). MNC (3-5 × 10 6 ) were seeded into cultures (DCE/DIA (daunorubicin, cytosine arabinoside, etoposide/daunorubicin, cytosine arabinoside) (n = 6), containing a feeder layer of irradiated (8000 cGy) murine M2-10B4 cells (3 × 10 4 /cm 2 , kindly provided by Dr C ICE/IDIA (idarubicin, cytosine arabinoside, etoposide/ idarubicin, cytosine arabinoside) (n = 6), MICE/NOVIA Eaves, Terry Fox Laboratories, Vancouver, Canada) engineered by retroviral gene transfer to produce human IL-3 (mitoxantrone, cytosine arabinoside, etoposide/ mitoxantrone, cytosine arabinoside) (n = 5) ), containing the and human G-CSF. 20 Cultures were fed weekly by replacement of half the growth medium containing half the nonadsame intercalating drug during induction and consolidation phase. 13 Bone marrow cultures were performed before (n herent cells with fresh complete medium. After 5 weeks in culture, nonadherent cells and adherent cells harvested by = 4) or after (n = 7) consolidation therapy or at marrow harvest (n = 15). The median time intervals from diagnosis trypsinization were pooled, washed and assayed together for clonogenic cells in standard methylcellulose cultures at to study were 122 days (range, 34-140), 142 days (range, 90-198) and 150 days (range, 114-248) for patients evaluan appropriate concentration (usually 5 × 10 4 /ml). The total number of clonogenic cells (ie CFU-Mix plus BFU-E plus ated before consolidation therapy, after consolidation ther-CFU-GM) present in 5-week-old LTC provides a relative data (two-tail) was used to test the probability of significant differences between samples. measure of the number of LTC-IC originally present in the test suspension.
21 Absolute LTC-IC values were calculated by dividing the total number of clonogenic cells by four, which is the average output of clonogenic cells per LTCResults IC, according to limiting dilution analysis studies reported by others.
21

Hematopoietic progenitors
Hematopoietic progenitor cell growth was evaluated in the bone marrow of 26 AML patients who had achieved comAssays of the hematopoietic microenvironment plete hematological remission with four different protocols In order to evaluate the effect of remission induction and of remission induction and consolidation. 13 At the time of consolidation therapy on marrow microenvironment, the the study, 22 patients had received remission induction and incidence of CFU-F and the capacity of marrow cells to consolidation therapy, whereas four cases (Nos 16, 18, 19, generate stromal layers were analyzed. The assay for CFU-24) had only received remission induction therapy. Blood F was performed according to Castro-Malaspina et al. 16 values and marrow morphology were normal and no patient Briefly, 4 ml of marrow MNC (5 × 10 4 /ml) resuspended in had marrow fibrosis. For the entire group of AML patients complete alpha-medium were plated in 60-mm Petri dishes (n = 26), the median interval between diagnosis and study and fibroblast colony growth was evaluated after incubation was 145 days (range, 34-248). (37°C, 5% CO 2 ) for 14 days in a humidified atmosphere. Table 1 shows that, as compared to normal controls (n Four dishes were set up for each individual data point per = 57), AML patients showed a statistically significant experiment. For scoring CFU-F, the dishes were stained reduction of the mean (±s.e.m.) number of multipotent with crystal violet and examined under an inverted micro-CFU-Mix (5.3 ± 0.6 vs 0.8 ± 0.2, P р 0.0001), erythroid scope. Fibroblastoid cell aggregates of у50 cells were BFU-E (68 ± 5 vs 20 ± 4, P р 0.0001), and granulocytescored as CFU-F. To generate marrow stromal layers, the macrophage CFU-GM (198 ± 11 vs 144 ± 15, P р 0.008). method of Dexter et al 1 was used with slight modifications. Briefly, 6-ml aliquots of marrow MNC (1 × 10 6 /ml) resus- Cupertino, CA, USA). The Student's t-test for unpaired A statistically significant growth reduction was also dose chemotherapy regimens used in AML patients were not able to quantitatively damage marrow CFU-F. observed for the primitive LTC-IC progenitors which were reduced on average by six-fold as compared to normal conTo characterize the marrow microenvironent at a functional level, the formation of stromal layers and their capatrols (302 ± 46 vs 50 ± 8, P р 0.001).
As compared to controls, AML patients studied at the bility to support the growth of allogeneic hematopoietic progenitors were analyzed. As shown in Table 2 , 62% of time of marrow harvest (n = 15) showed a persistent reduction of LTC-IC (302 ± 46 vs 55 ± 11, P р 0.008) AML patients generated a confluent stroma whereas 19% generated a subconfluent layer and 19% failed to produce associated with normalization of CFU-GM growth (198 ± 11 vs 167 ± 16, P р 0.2). No substantial difference any kind of adherent stromal layer. In contrast, nearly all (95%) normal marrow samples (n = 28) used as control in the incidence of committed and primitive progenitors was observed when AML patients were stratified according produced a confluent marrow stroma with only two samples resulting in subconfluent growth and no sample showing to the different induction and consolidation regimens, or inclusion in the pilot or randomized AML10 trial.
absence of stromal layer. Adipocyte formation was evident in 62% of AML patients and 100% of normal samples ( Table 2) . No difference between normal and AML was Microenvironment progenitors observed in terms of time to reach the confluence and time of appearance of adipocytes. In contrast to hematopoietic progenitors, the mean (± s.e.m.) incidence of fibroblastic progenitors was not sigThirteen confluent and four subconfluent AML stromal layers could be tested for their capacity to support the nificantly reduced as compared to normal controls (48 ± 6 vs 52 ± 7, P р 0.73) ( Table 2) . No difference in CFU-F growth of allogeneic peripheral blood LTC-IC. Seven AML stromal layers, including five confluent and two subconflugrowth could be detected when AML patients were stratified according to time of the study (preconsolidation vs ent layers, failed to support any progenitor cell growth, whereas seven AML samples, including six confluent and post-consolidation vs harvest), different induction-consolidation regimens, inclusion in the pilot or randomized one subconfluent stromal cultures, had a markedly defective supportive capacity which was significantly lower as com-AML10 trial. Overall, these results suggest that standardpared to normal marrow-derived stromal layers (13 ± 5 vs 249 ± 56, P р 0.002) (Figure 1 ). a Mean (± s.e.m.) CFU-F generated by normal controls (n = 28) were 52 ± 7 (P р 0.73). mental progenitor cells were damaged in these patients. In stantial contribution of CFU-GM in the early phase of engraftment. Indeed, using a homogeneous population of agreement with previously published papers, data reported herein clearly demonstrate that patients with AML treated primitive human hematopoietic cells, in vitro evidence has been provided suggesting the existence of a mechanism that with anthracycline-or mitoxantrone-containing regimens have a significant reduction of primitive (LTC-IC) and can provide both short-term and long-term hematopoietic repopulation. 37 Therefore, the marked LTC-IC reduction committed (CFU-Mix, BFU-E, CFU-GM) marrow progenitors. [25] [26] [27] In our patients, progenitor cell damage was detected in our AML patients might be viewed as one biologically relevant factor conditioning the prolonged detected at the time they achieved complete remission following induction chemotherapy and was still evident at the pancytopenia associated with increased transplant-related mortality observed following ABMT. time of marrow harvest when, despite a substantial evidence of CFU-GM regeneration, as suggested by the norThe CFU-F assay identifies a class of clonogenic fibroblast progenitors 38 which belong to the osteogenic stromal mal incidence of these progenitors, primitive LTC-IC remained markedly reduced. It has been shown that followlineage 39 and play an important role in establishing the hematopoietic microenvironment both in vitro and in ing a cytotoxic insult, self-renewal of stem cells takes precedence over differentiation usually allowing the stem cell vivo. 3,40 Ectopic transplantation of individual fibroblastic clones grown in vitro from mouse marrow beneath the renal system to recover to a normal level. 28 In our study population, we could demonstrate CFU-GM, but not LTC-IC capsule of syngeneic hosts demonstrated that approximately 15% produced a marrow organ containing the full spectrum regeneration. The persistent derangement of the LTC-IC compartment associated with a normal CFU-GM incidence of stromal cell types of the hematopoietic microenvironment. 4 ,5 A proportion of marrow CFU-F cultured in the suggests a permanent defect, due to an irreversible toxic effect of chemotherapy, rather than a transient phenomenon presence of hydrocortisone is induced to adipogenesis.
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In vivo as well as in vitro chemotherapy has been shown related to the short time interval between chemotherapy administration and time of the study.
to damage marrow stroma. 7,25,41, 42 We demonstrate that AML marrow has a maintained CFU-F incidence but fails The association of a decreased number of hematopoietic progenitors with normal peripheral blood counts indicates to generate confluent stromal layers in a significant percentage of cases. This suggests that fibroblastic progenitors, that the hematopoietic system is capable of compensating for the deficiency of early hematopoietic progenitor cells, although quantitatively normal, are functionally altered in that they have lost their proliferative and differentiative as previously shown in patients who have undergone highly aggressive chemotherapy or allogeneic bone marrow transpotential which substantially contribute to the generation of a confluent marrow stroma. 4,5 Four patients (cases 3, 4, 10 plantation. 29 The reduced number of hematopoietic progenitors coexisting with normal white blood cell counts and 13) exhibited growth of CFU-F but failed to generate stromal cell layers in LTC culture conditions. Differences suggests an inverse relationship between the differentiative capacity and potential for stem cell self-renewal. 29 This in cell concentration, frequency of medium change, scoring time and culture duration, which distinguish the culture sysimplies that in our AML patients an increased demand on stem cells for differentiation takes precedence over the tems we used to grow CFU-F or generate stromal layers, might only partially explain the discrepancy between demand for self-renewal, thus compensating for maintaining the supply of end cells to the peripheral blood. Such growth of CFU-F and failure to generate stromal cell layers. Since stromal layers are generated either by a stromal stem a mechanism might explain the LTC-IC damage we detected in AML patients evaluated at the time of marcell(s) or different classes of progenitor(s) which include, but are not limited to CFU-F, 3 we hypothesize that in some row harvest.
Despite recent evidence demonstrating that the LTC-IC patients chemotherapy-induced stromal toxicity might preferentially affect stromal progenitors other than CFU-F and assay detects a class of primitive stem cells with phenotypic characteristics of transplantable murine in vivo repopulating this might translate into failure of stromal layer generation in 5-week-old LTC associated with growth of day-14 cells 30 and self-renewal potential, 31 the role of primitive LTC-IC in promoting hematopoietic recovery following CFU-F. Either a complete failure or a markedly defective SCT as well as the dose of these progenitors which is required for a prompt and durable engraftment is still a capacity of AML stroma to support the growth of allogeneic normal hematopoietic progenitors was observed. matter of controversy. Distinct subsets of stem cells may be responsible for different phases of engraftment after
The number of stromal cells in confluent cultures was not assessed on a routine basis. However, in preliminary stem cell transplantation. 32, 33 Murine studies in which isoenzyme analysis and retroviral gene marking of hematopoexperiments, counting of confluent stromal layers following trypsinization did not reveal significant quantitative variietic cells have been used to track the fate of stem cells support the existence of short-term and long-term reconstiation from patient to patient. Since the evidence of a defective supportive function was derived from six confluent, tuting stem cell populations. [34] [35] [36] In human subjects there is no clear evidence for the separation of distinct subsets and only one subconfluent, stromal cell layers, we assume that the defective supportive ability of AML stroma is due of cells with differing repopulating potentials. A functional heterogeneity of transplantation potential of human stem to qualitative differences in stromal cell function rather than quantitative differences in the number of stromal cells. cells can be argued from recipients of mobilized peripheral blood SCT who have a rapid hematopoietic reconstitution Under physiological conditions, stromal cells of the hematopoietic microenvironment include fibroblasts, endosuggesting either that mobilized peripheral blood is enriched for short-term repopulating stem cells or a subthelial cells, adipocytes and macrophages. 2 'engraftment facilitating cells', which are donor-derived
